Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MVCD1
MCID: MCR129
MIFTS: 66

Microvascular Complications of Diabetes 1 (MVCD1)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Microvascular Complications of Diabetes 1

About this section

MalaCards integrated aliases for Microvascular Complications of Diabetes 1:

Name: Microvascular Complications of Diabetes 1 56 73 29 13 6 39
Proliferative Diabetic Retinopathy 12 73 54 15 17 71
Non-Proliferative Diabetic Retinopathy 73 17
Diabetic Nephropathy 73 71
Mvcd1 56 73
Microvascular Complications of Diabetes, Susceptibility to, 1 56
Nonproliferative Retinopathy, Diabetic, Susceptibility to 56
Proliferative Retinopathy, Diabetic, Susceptibility to 56
Nonproliferative Retinopathy, Diabetic 56
Nonproliferative Diabetic Retinopathy 71
Proliferative Retinopathy, Diabetic 56
Complications of Diabetes Mellitus 71
Diabetic End-Stage Renal Disease 73
Diabetes Complications 43
Diabetic Neuropathies 71
Diabetic Neuropathy 73
Pdr 12

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Cardiovascular diseases Neuronal diseases Nephrological diseases Eye diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:13207
OMIM 56 603933
OMIM Phenotypic Series 56 PS603933
ICD9CM 34 362.02
MeSH 43 D048909
NCIt 49 C84457
SNOMED-CT 67 59276001
UMLS 71 C0004606 C0011881 C0011882 more
Sources

Summaries for Microvascular Complications of Diabetes 1

About this section
UniProtKB/Swiss-Prot : 73 Microvascular complications of diabetes 1: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 1, also known as proliferative diabetic retinopathy, is related to background diabetic retinopathy and diabetic autonomic neuropathy, and has symptoms including sciatica and neuralgia. An important gene associated with Microvascular Complications of Diabetes 1 is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Zaleplon and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include endothelial, eye and kidney, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Wikipedia : 74 Complications of diabetes mellitus include problems that develop rapidly (acute) or over time (chronic)... more...

More information from OMIM: 603933 PS603933
Sources

Related Diseases for Microvascular Complications of Diabetes 1

About this section

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 960)
# Related Disease Score Top Affiliating Genes
1 background diabetic retinopathy 33.4 VEGFA INS ICAM1 ANGPT2 AKR1B1 AGER
2 diabetic autonomic neuropathy 33.4 NTF3 NGF INS AKR1B1
3 severe nonproliferative diabetic retinopathy 33.4 VEGFA INS ICAM1 CCL2 AKR1B1
4 macular holes 32.0 VEGFA SERPINF1 CCL2 ANGPT2
5 renal fibrosis 31.9 MMP9 HGF CCN2 CCL2
6 glomerulonephritis 31.6 VCAM1 ICAM1 CCN2 CCL2
7 diabetic polyneuropathy 31.5 VEGFA NTF3 NGF INS AKR1B1 AGER
8 preretinal fibrosis 31.4 VEGFA HGF ANGPT2
9 retinal ischemia 31.4 VEGFA ICAM1 FGF2 CXCL12
10 sensory peripheral neuropathy 31.3 NTF3 NGF AKR1B1
11 microvascular complications of diabetes 3 31.3 INS CCN2 AKR1B1 AGER
12 endophthalmitis 31.2 VEGFA ICAM1 FLT1 CXCL8
13 nephrosclerosis 31.2 VEGFA INS CCN2 CCL2
14 uveitis 31.1 SERPINF1 ICAM1 CXCL8 CCL2
15 retinal microaneurysm 31.0 VEGFA INS AKR1B1
16 autonomic neuropathy 31.0 NTF3 NGF INS AKR1B1
17 hyperglycemia 31.0 VCAM1 SST INS IGF1 AKR1B1 AGER
18 neuritis 30.8 MMP9 CXCL8 CCL2
19 carpal tunnel syndrome 30.8 VEGFA INS FGF2 CCN2 CCL2
20 leptospirosis 30.8 ICAM1 CXCL8 CCL2
21 arteries, anomalies of 30.8 VEGFA VCAM1 INS ICAM1 CCL2
22 proteasome-associated autoinflammatory syndrome 1 30.7 VCAM1 MMP9 ICAM1 CXCL8 CCL2
23 polyneuropathy 30.7 VEGFA NGF INS AKR1B1
24 neurogenic arthropathy 30.7 NGF INS
25 plasmodium vivax malaria 30.7 VCAM1 ICAM1 ANGPT2
26 hypoglycemia 30.7 VEGFA SST INS IGF1
27 macular dystrophy, dominant cystoid 30.7 VEGFA SERPINF1 CXCL12
28 diabetic angiopathy 30.7 VCAM1 INS CCL2 AGER
29 retinal vein occlusion 30.7 VEGFA SERPINF1 CXCL8 CXCL12 CCL2 ANGPT2
30 fibromyalgia 30.7 NGF IGF1 CXCL8 CCL2
31 vascular cancer 30.6 VEGFA FLT1 FGF2
32 arteriosclerosis obliterans 30.6 VCAM1 ICAM1 HGF
33 myopia 30.6 VEGFA SERPINF1 IGF1 HGF FGF2
34 diabetic encephalopathy 30.6 NGF INS IGF1
35 tuberous sclerosis 30.6 VEGFA SST INS IGF1
36 peritonitis 30.6 VCAM1 ICAM1 CXCL8 CCL2
37 crescentic glomerulonephritis 30.6 VCAM1 ICAM1 CCN2 CCL2
38 autoimmune disease 30.6 VCAM1 MMP9 INS CXCL8 CCL2
39 neovascular glaucoma 30.5 VEGFA FLT1 FGF2 CXCL8
40 peripheral vascular disease 30.5 VEGFA VCAM1 INS CCL2
41 placenta disease 30.5 VEGFA INS FLT1 CXCL8
42 cerebrovascular disease 30.5 VCAM1 MMP9 INS ICAM1 AGER
43 cardiovascular system disease 30.5 VCAM1 INS IGF1 ICAM1 CCL2 AGER
44 carotid stenosis 30.5 VEGFA VCAM1 MMP9 ICAM1 CXCL8
45 severe pre-eclampsia 30.5 VEGFA VCAM1 MMP9
46 rhinitis 30.5 VCAM1 NGF ICAM1 CXCL8
47 retinal artery occlusion 30.5 VEGFA ICAM1 FLT1 CCL2
48 osteonecrosis 30.5 VEGFA IGF1 FGF2
49 intermittent claudication 30.4 VEGFA IGF1 FGF2 ANGPT2
50 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 30.4 INS IGF1

Comorbidity relations with Microvascular Complications of Diabetes 1 via Phenotypic Disease Network (PDN): (show all 21)


Acute Cystitis Acute Kidney Failure
Benign Essential Hypertension Decubitus Ulcer
Deficiency Anemia Diabetic Cataract
Diabetic Polyneuropathy Heart Disease
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Iron Deficiency Anemia
Kidney Disease Microvascular Complications of Diabetes 7
Mitral Valve Disease Neurogenic Arthropathy
Peripheral Vascular Disease Rubeosis Iridis
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 1:



Diseases related to Microvascular Complications of Diabetes 1
Sources

Symptoms & Phenotypes for Microvascular Complications of Diabetes 1

About this section

Clinical features from OMIM:

603933

UMLS symptoms related to Microvascular Complications of Diabetes 1:


sciatica, neuralgia

GenomeRNAi Phenotypes related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 AGER AKR1B1 CCL2 CXCL8 IGF1 NTF3

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 1:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 AGER ANGPT2 CCN2 CXCL12 FGF2 FLT1
2 growth/size/body region MP:0005378 10.37 AGER AKR1B1 CCN2 FLT1 HGF ICAM1
3 homeostasis/metabolism MP:0005376 10.37 AGER AKR1B1 ANGPT2 CCN2 FGF2 FLT1
4 cellular MP:0005384 10.36 AGER ANGPT2 CCN2 CXCL12 FGF2 FLT1
5 mortality/aging MP:0010768 10.34 AKR1B1 ANGPT2 CCN2 CXCL12 FGF2 FLT1
6 hematopoietic system MP:0005397 10.29 AGER CXCL12 FGF2 FLT1 HGF ICAM1
7 immune system MP:0005387 10.29 AGER ANGPT2 CCL2 CXCL12 FLT1 ICAM1
8 nervous system MP:0003631 10.15 CXCL12 FGF2 FLT1 ICAM1 IGF1 INS
9 digestive/alimentary MP:0005381 10.14 ANGPT2 CCN2 ICAM1 INS MMP9 SERPINF1
10 muscle MP:0005369 10.14 AGER CXCL12 FGF2 FLT1 ICAM1 IGF1
11 integument MP:0010771 10.11 AGER ANGPT2 CCN2 ICAM1 IGF1 INS
12 normal MP:0002873 9.96 AGER CCN2 CXCL12 FLT1 IGF1 INS
13 no phenotypic analysis MP:0003012 9.87 CXCL12 HGF INS NGF SST VCAM1
14 reproductive system MP:0005389 9.85 CXCL12 FGF2 FLT1 IGF1 INS MMP9
15 skeleton MP:0005390 9.65 AGER AKR1B1 CCN2 FGF2 IGF1 INS
16 vision/eye MP:0005391 9.4 AKR1B1 ANGPT2 CCN2 FGF2 FLT1 ICAM1
Sources

Drugs & Therapeutics for Microvascular Complications of Diabetes 1

About this section

Drugs for Microvascular Complications of Diabetes 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 600)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
2
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
3
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
4
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
5
Methyldopa Approved Phase 4 555-30-6 38853
6
Saxagliptin Approved Phase 4 361442-04-8 11243969
7
Alogliptin Approved Phase 4 850649-61-5 11450633
8
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
9
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
10
Bevacizumab Approved, Investigational Phase 4 216974-75-3
11
Ranibizumab Approved Phase 4 347396-82-1 459903
12
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
13
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
14
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
15
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
16
Histamine Approved, Investigational Phase 4 51-45-6 774
17
Dipivefrin Approved Phase 4 52365-63-6 3105
18
Amitriptyline Approved Phase 4 50-48-6 2160
19
Acetaminophen Approved Phase 4 103-90-2 1983
20 Grape Approved Phase 4
21
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
22
Losartan Approved Phase 4 114798-26-4 3961
23
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
24
Insulin lispro Approved Phase 4 133107-64-9
25
Povidone-iodine Approved Phase 4 25655-41-8
26
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
27
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
28
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
29
Probucol Approved, Investigational Phase 4 23288-49-5 4912
30
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
31
Ramipril Approved Phase 4 87333-19-5 5362129
32
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
33
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
34
Doxazosin Approved Phase 4 74191-85-8 3157
35
Atorvastatin Approved Phase 4 134523-00-5 60823
36
Indapamide Approved Phase 4 26807-65-8 3702
37
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
38
Nisoldipine Approved Phase 4 63675-72-9 4499
39
Trandolapril Approved Phase 4 87679-37-6 5484727
40
Amlodipine Approved Phase 4 88150-42-9 2162
41
Verapamil Approved Phase 4 52-53-9 2520
42
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
43
Insulin glulisine Approved Phase 4 207748-29-6
44
Febuxostat Approved Phase 4 144060-53-7 134018
45
Allopurinol Approved Phase 4 315-30-0 2094
46
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
47
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
48
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
49
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
50
Atenolol Approved Phase 4 29122-68-7 2249

Interventional clinical trials:

(show top 50) (show all 1415)
# Name Status NCT ID Phase Drugs
1 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
2 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
3 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
4 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
5 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
6 Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN) Unknown status NCT01770964 Phase 4 Pregabalin;placebo
7 A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
8 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
9 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
10 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
11 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
12 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
13 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
14 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
15 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
16 Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial. Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
17 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
18 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
19 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
20 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
21 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
22 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
23 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
24 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
25 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
26 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
27 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
28 A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes. Unknown status NCT00749047 Phase 4 Pioglitazone
29 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
30 Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery Unknown status NCT02535000 Phase 4 Duloxetine;Placebo
31 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
32 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
33 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
34 Effects of Pregabalin on Mechanical Hyperalgesia - EPOM Unknown status NCT00310583 Phase 4 Pregabalin
35 Effects of the DPP-4 or SGLT2 Inhibitors on the Metabolic Cardiovascular Systems in Patients With Type 2 Diabetes Mellitus. Unknown status NCT02528019 Phase 4 DPP-4 inhibiotors;SGLT2 inhibitors;Glimepiride
36 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
37 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
38 The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine Unknown status NCT03659383 Phase 4
39 Attenuation of Spinal Induced Hypotension With Granisetron in Type I Diabetic Parturients Unknown status NCT03091881 Phase 4 Granisetron 0.1 MG/ML;Placebos
40 Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab. Completed NCT00801866 Phase 4 Bevacizumab
41 Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area Completed NCT02834663 Phase 4 Lucentis
42 Effect of Adjunctive Intravitreal Bevacizumab Before Panretinal Photocoagulation in Macular Thickness and Retinal Nerve Fiber Layer Thickness Completed NCT01504724 Phase 4 bevacizumab
43 Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain Completed NCT00322621 Phase 4 Duloxetine
44 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
45 The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients Completed NCT04238208 Phase 4 Lidocaine 5% patch;Capsaicin 8% Patch, Per 10 Square Centimeters
46 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
47 Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies Completed NCT02842554 Phase 4 Drug Placebo Administration
48 An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy Completed NCT00644748 Phase 4 gabapentin
49 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
50 A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00266643 Phase 4 duloxetine hydrochloride

Search NIH Clinical Center for Microvascular Complications of Diabetes 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Becaplermin
benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
Captopril
Citalopram
Citalopram hydrobromide
COBALAMIN CONCENTRATE
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
Hydroxocobalamin
HYDROXOCOBALAMIN ACETATE
irbesartan
Lisinopril
Losartan
Losartan Potassium
mecobalamin
Mexiletine
Mexiletine Hydrochloride
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Pentoxifylline
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan
Vitamin B 12

Cochrane evidence based reviews: diabetes complications

Sources

Genetic Tests for Microvascular Complications of Diabetes 1

About this section

Genetic tests related to Microvascular Complications of Diabetes 1:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 1 29 VEGFA
Sources

Anatomical Context for Microvascular Complications of Diabetes 1

About this section

MalaCards organs/tissues related to Microvascular Complications of Diabetes 1:

40
Endothelial, Eye, Kidney, Retina, Testes, Bone, Spinal Cord
Sources

Publications for Microvascular Complications of Diabetes 1

About this section

Articles related to Microvascular Complications of Diabetes 1:

(show top 50) (show all 4203)
# Title Authors PMID Year
1
A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. 6 56 61
11978667 2002
2
Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. 61 54 56
15767056 2005
3
SDF-1 is both necessary and sufficient to promote proliferative retinopathy. 61 54 56
15630447 2005
4
Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. 56 54 61
12208249 2002
5
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. 61 56
17259996 2007
6
Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. 56
20522428 2010
7
Genetic analysis of diabetic nephropathy on chromosome 18 in African Americans: linkage analysis and dense SNP mapping. 56
19690890 2009
8
Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. 56
19881493 2009
9
Association of genetic variants at 3q22 with nephropathy in patients with type 1 diabetes mellitus. 56
19084216 2009
10
Sequence variants in the PLEKHH2 region are associated with diabetic nephropathy in the GoKinD study population. 56
18752002 2008
11
High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach. 56
18559660 2008
12
Association of CC chemokine ligand 5 genotype with urinary albumin excretion in the non-diabetic Japanese general population: the Takahata study. 56
18217191 2008
13
Genetic factors in diabetic nephropathy. 56
17942768 2007
14
Promoter polymorphisms of the pigment epithelium-derived factor gene are associated with diabetic retinopathy. 56
17658465 2007
15
Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 -455T>C polymorphisms on the susceptibility to diabetic nephropathy. 56
16813599 2006
16
A genome-wide DNA microsatellite association screen to identify chromosomal regions harboring candidate genes in diabetic nephropathy. 56
16467450 2006
17
Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. 56
15793258 2005
18
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. 56
15599399 2004
19
A genome scan for diabetic nephropathy in African Americans. 56
15458446 2004
20
RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. 56
12610055 2003
21
Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. 56
12480514 2003
22
Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. 56
12427143 2002
23
Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. 56
12208245 2002
24
Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. 56
11918623 2002
25
Transforming growth factor beta contributes to progressive diabetic nephropathy. 56
10884396 2000
26
Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. 56
10884438 2000
27
Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. 56
10859350 2000
28
Genetics of diabetic nephropathy: evidence for major and minor gene effects. 56
10201028 1999
29
Aldose reductase gene expression is increased in diabetic nephropathy. 56
9215310 1997
30
Familial factors determine the development of diabetic nephropathy in patients with IDDM. 56
8858216 1996
31
Molecular genetic analysis of the human sorbitol dehydrogenase gene. 56
8535074 1995
32
Acetylator phenotype in diabetic neuropathy. 56
871863 1977
33
Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. 61 54
20453802 2010
34
Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: Analysis of vitreous samples. 54 61
20015663 2010
35
Transcription factor, SP1, in epiretinal membranes of patients with proliferative diabetic retinopathy. 54 61
20047772 2010
36
Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress, and VEGF in the vitreous body. 61 54
20142849 2010
37
Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. 54 61
19837381 2009
38
Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients. 54 61
20011081 2009
39
Immunohistochemical analysis of cellular adhesion molecules (ICAM-1, VCAM-1) and VEGF in fibrovascular membranes of patients with proliferative diabetic retinopathy: preliminary study. 54 61
18834676 2009
40
Vascular endothelial growth factor-A (VEGF-A) in vitreous fluid of patients with proliferative diabetic retinopathy. 54 61
20214050 2009
41
Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. 54 61
19410951 2009
42
Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. 61 54
19484443 2009
43
Proliferative diabetic retinopathy-The influence of diabetes control on the activation of the intraocular molecule system. 61 54
19237221 2009
44
[The expression of vascular endothelial growth factor of vitreous in patients with proliferative diabetic retinopathy]. 61 54
19575912 2009
45
Ratio of the vitreous vascular endothelial growth factor and pigment epithelial-derived factor in Eales disease. 61 54
20072643 2009
46
Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. 54 61
19219687 2009
47
Vitreous levels of vasohibin-1 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. 61 54
19057892 2009
48
Diabetic retinopathy and angiogenesis. 54 61
19199892 2009
49
PEDF inhibits VEGF- and EPO- induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation. 61 54
19657716 2009
50
Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. 61 54
18633446 2009
Sources

Variations for Microvascular Complications of Diabetes 1

About this section

ClinVar genetic disease variations for Microvascular Complications of Diabetes 1:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 VEGFA NM_001025366.3(VEGFA):c.-94C>GSNV risk factor 12223 rs2010963 6:43738350-43738350 6:43770613-43770613
Sources

Expression for Microvascular Complications of Diabetes 1

About this section
Search GEO for disease gene expression data for Microvascular Complications of Diabetes 1.
Sources

Pathways for Microvascular Complications of Diabetes 1

About this section

Pathways related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Apoptotic Pathways in Synovial Fibroblasts 63
Show member pathways
 13.89 SERPINF1 NTF3 NGF MMP9 INS IGF1
2
ERK Signaling 63
Show member pathways
 13.87 VEGFA NTF3 NGF IGF1 HGF FLT1
3
GPCR Pathway 63
Show member pathways
 13.74 VEGFA NTF3 NGF MMP9 IGF1 HGF
4
PEDF Induced Signaling 63
Show member pathways
 13.72 SERPINF1 NGF INS HGF FLT1 CXCL8
5
Activation of cAMP-Dependent PKA 63
Show member pathways
 13.58 NTF3 NGF IGF1 HGF FLT1 FGF2
6
Akt Signaling 63
Show member pathways
 13.46 NTF3 NGF IGF1 HGF FLT1 FGF2
7
Cytokine Signaling in Immune system 65
Show member pathways
 13.41 VEGFA VCAM1 MMP9 ICAM1 HGF FGF2
8
CREB Pathway 63
Show member pathways
 13.38 NTF3 NGF IGF1 HGF FLT1 FGF2
9
TGF-Beta Pathway 63
Show member pathways
 13.34 VEGFA NTF3 NGF INS IGF1 ICAM1
10
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.33 VEGFA NTF3 NGF IGF1 HGF FLT1
11
PAK Pathway 63
Show member pathways
 13.32 NTF3 NGF IGF1 HGF FLT1 FGF2
12
Phospholipase-C Pathway 63
Show member pathways
 13.13 NTF3 NGF IGF1 HGF FLT1 FGF2
13
PI3K-Akt signaling pathway 36
Show member pathways
 13.06 VEGFA NTF3 NGF INS IGF1 HGF
14
Human cytomegalovirus infection 36
Show member pathways
 13 VEGFA ICAM1 FGF2 CXCL8 CXCL12 CCL2
15
p70S6K Signaling 63
Show member pathways
 12.99 VCAM1 NTF3 NGF INS IGF1 HGF
16
Pathways in cancer 36
12.92 VEGFA MMP9 IGF1 HGF FGF2 CXCL8
17
Allograft rejection 1 36
Show member pathways
 12.87 VEGFA INS ICAM1 CXCL8 CXCL12
18
NF-KappaB Family Pathway 63
Show member pathways
 12.77 NTF3 NGF IGF1 HGF FLT1 FGF2
19
MAPK signaling pathway 36 1
12.75 VEGFA NTF3 NGF INS IGF1 HGF
20
Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling 64
Show member pathways
 12.72 VEGFA VCAM1 MMP9 ICAM1 CXCL12 CCL2
21
Ras signaling pathway 36
Show member pathways
 12.7 VEGFA NTF3 NGF INS IGF1 HGF
22
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.49 NTF3 NGF IGF1 HGF FLT1 FGF2
23
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.42 VEGFA VCAM1 ICAM1 CCL2
24
Proteoglycans in cancer 36
12.38 VEGFA MMP9 IGF1 HGF FGF2
25
Transcriptional misregulation in cancer 36
12.3 MMP9